

LETTER TO THE EDITOR

Prior ESHAP treatment and risk for mobilization failure

To the editor,

We read with interest the paper by Ebisawa and colleagues describing the use of febrile neutropenia (D-index) as a predictor for poor mobilization in patients undergoing peripheral blood stem cell (PBSC) collection after chemotherapy mobilization.¹ What caught our eye was the treatment-related chemotherapy used for mobilization in their patient cohort. To minimize patient heterogeneity, the authors applied the D-index only to patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) mobilized with G-CSF and ESHAP (etoposide, cytarabine [ara-C], methylprednisolone, cisplatin) or a modified ESHAP regimen (etoposide, ara-C, methylprednisolone, carboplatin). Although ESHAP is a common second-line salvage regimen used in NHL, it can be associated with poor mobilization in 10% to 20% of patients. In an older retrospective study of 78 NHL patients collected after ESHAP, 20% failed to collect a minimum transplant dose of 2×10^6 CD34/kg after two leukapheresis procedures.² A smaller study of 20 NHL patients collected after second line treatment with ESHAP (1-3 cycles) also reported a 20% failure rate.³ A more recent study using brentuximab and ESHAP as salvage for relapsed Hodgkin's lymphoma found good CD34 yields when patients were collected after their first cycle of ESHAP; however, there was a marked reduction in yields after a second cycle.⁴ In the current study by Ebisawa et al., 5/58 (9%) of patients failed to collect a minimum dose of 1 to 2×10^6 CD34/kg/procedure after 2 to 3 cycles of ESHAP.¹

We would like to share our experience with PBSC collection in patients mobilized with high-dose cyclophosphamide (CTX), after prior treatment with ESHAP. Over 10 years ago, there was an institutional trial in refractory/relapsed NHL, which required in vivo purging with rituximab (375 mg/m^2 weekly $\times 4$) followed by chemotherapy mobilization using CTX (4 g/m^2) and G-CSF (10 mcg/kg). Of note, the trial was conducted prior to FDA approval and widespread availability of plerixafor. All patients were relapsed NHL ($n = 35$; 25 diffuse B-cell, four follicular, six mantle cell) with a median of two prior chemotherapy regimens and nine chemotherapy cycles. Seven patients (20%) received 2 to 3 cycles of ESHAP as second line treatment prior to rituximab and CTX

mobilization. Among ESHAP patients, the majority required four or more leukapheresis (71% vs. 18% non-ESHAP, $P = .006$; OR = 11.5 [95% CI: 1.7-77.2]) with 81% (21/26) procedures yielding $<0.5 \times 10^6$ CD34/kg ($P = .0001$; OR 7.5 [95% CI: 2.5-22]). The average CD34 yield/procedure was $0.60 \pm 0.82 \times 10^6/\text{kg}$ in ESHAP vs $1.64 \times 10^6/\text{kg}$ in non-ESHAP patients ($P = .003$), with a median total CD34 yield/mobilization = $2.1 \times 10^6/\text{kg}$ ESHAP (vs $3.84 \times 10^6/\text{kg}$ non-ESHAP, $P = .017$). ESHAP patients accounted for 50% (3/6) of all mobilization failures ($P = .047$). There was no significant difference in patient demographics or number of prior chemotherapy cycles between ESHAP and non-ESHAP patients. Our results stress the importance of collecting NHL patients shortly after initiating ESHAP salvage chemotherapy. In patients with prior ESHAP therapy, we suggest early upfront use of plerixafor due to the high risk of mobilization failure.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Author declines to share data due to privacy/ethic concerns.

Laura Cooling 

Sandra Hoffmann

Department of Pathology, Michigan Medicine, University of Michigan Hospitals, Ann Arbor, Michigan, USA

Correspondence

Laura Cooling, Department of Pathology, Michigan Medicine, University of Michigan Hospitals, Ann Arbor, MI 48109-0054, USA.

Email: lcooling@med.umich.edu

ORCID

Laura Cooling  <https://orcid.org/0000-0003-0216-1599>

REFERENCES

1. Ebisawa K, Honda A, Chiba A, et al. High D-index during mobilization predicts poor mobilization of CD34+ cells after anti-lymphoma salvage chemotherapy. *J Clin Apher.* 2021;1-9. doi:10.1002/jca.21943

2. Watts MJ, Ings SJ, Leverett D, et al. ESHAP and G-CSF is a superior blood stem mobilizing regimen compared to cyclophosphamide 1.5 gm m⁻² and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. *Br J Cancer*. 2000;82(2):278-282.
3. Liu J-H, Chen C-C, Bai L-Y, Chao SC, Chang MS, Lin JS. Predictors for successful mobilization of peripheral blood progenitor cells with ESHAP + G-CSF in patients with pretreated non-Hodgkin's lymphoma. *J Chin Med Assoc*. 2008;71(6):279-285.
4. Garcia-Sanz R, Sureda A, de la Cruz F, et al. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term result of a trial by the Spanish GELTAMO group). *Ann Oncol*. 2019;30(4):612-620.